Moleculin Biotech is trading 6.5% up at $1.09 in pre-market action, showing signs of stabilization following two days of heavy losses.
- The stock recently plummeted from $2.19 to $1.02, which included a sharp 37.9% decline during the July 30 session.
- No company-specific news has been identified as the driver for the recent selling pressure or the current rebound.
- The move appears to be a modest technical recovery in a volatile, beaten-down name supported by a broadly positive market tone.